Leading article
The ursodeoxycholic acid story in primary biliary cirrhosis
The name ursodeoxycholic acid (UDCA) is derived from 'ursocholeinische saure' used by Hammarsten in 1902 to describe a bile acid discovered in polar bears. The bile acid he identified was actually chenodeoxycholic acid.1 UDCA is the 7P epimer of chenodeoxycholic acid and has the chemical structure 3a 7 ,B-dihydroxy-5p-cholan-24-oic acid.2 Ten years ago, Leuschner et al3 made the serendipitous observation that UDCA given for gall stone dissolution noticeably improved routine liver function tests in patients who also had chronic liver disease. Since then, there have been reports of potential benefits in a wide range of cholestatic and chronic inflammatory liver conditions,4 but most is known about the use of UDCA in primary biliary cirrhosis (PBC). In this article, we first discuss the pathogenesis of PBC and possible mechanisms of action of UDCA, and then review its clinical efficacy.
Mechanisms of action of UDCA The pathophysiology of PBC can be considered as two processes. Firstly, immune damage directed at the intrahepatic bile ducts; and secondly, reduced bile flow (cholestasis) and retention of endogenous bile acids, which cause cytotoxic damage to the liver.4 5 There is accumulating evidence that UDCA may affect all these mechanisms.
IMMUNOMODULATOR
UDCA corrects some of the immune abnormalities previously described in PBC. Most prominent is the finding that UDCA reduces the aberrant expression of class 1 human leukocyte antigens (HLA 1) on hepatocytes.67 Although aberrant expression of major histocompatibility complexes is not a unique feature of PBC,8 they are important for recognition of hepatic tissue as targets by activated T lymphocytes. UDCA may also improve abnormalities in concentrations of circulating IgM9 10 interferon y,"l and activated T lymphocytes. 12 In vitro, the addition of UDCA can modulate the production of certain cytokines (interleukin 2, interleukin 4, and interleukin y) from human mononuclear cells. ' 19 We have recently used hepatoscintigraphy after intravenous injection of the y labelled bile acid 75sele-nium homocholic acid taurine (75SeHCAT), and quantified a defect in hepatic bile acid excretion in PBC patients. UDCA increased hepatic bile acid excretion.20 Not only is hepatic bile acid excretion affected by UDCA but so is ileal reabsorption of endogenous bile acids.2' 22 The net result of these effects on the enterohepatic bile acid circulation is alteration of the bile acid pool. The overall bile acid concentration rises by about 70%. 23 24 This rise is accompanied by a rise from 3% to over 60% in the proportion of the bile acid pool made up by UDCA.23-25 The proportion of unconjugated bile acids remains small (about 5%).
Whether the bile acid pool actually shifts towards hydrophilicity is uncertain. The proportion of cholic acid falls by about 40%2428 but the relative hydrophilicity of this bile acid is similar to UDCA. There are conflicting reports concerning the effects of treatment on the amount of chenodeoxycholic acid, the predominant retained hydrophobic bile acid.25 26 29 Although still controversial, a shift towards hydrophilicity is an attractive mechanism for the action of UDCA in PBC. Relatively hydrophobic bile acids such as chenodeoxycholic acid and deoxycholic acid are more damaging to cells than hydrophilic bile acids such as UDCA. Therefore enrichment of the bile acid pool with hydrophilic UDCA at the expense of hydrophobic endogenous bile acids would make it less toxic.
CYTOPROTECTION
There is also some evidence that UDCA has direct cytoprotective effects. In vitro, incubation of hepatocytes with chenodeoxycholic acid leads to leakage of cellular enzymes. The addition of UDCA to the incubation mixture reduces this damage.30 31 Hydrophobic bile acids certainly damage hepatocyte mitochondrial energy production32 and there is data from ourselves and others that UDCA protects energy production. 33 34 This cytoprotective effect is probably related to the ability of UDCA to protect membranes. 35 All four trials were large (150-220 patients each), had a study period of two years, and reported broadly similar results.9 10 23 40 Serum bilirubin and liver enzymes significantly improved and this improvement was sustained for two years. Improvement in IgM was observed in three trials9 1023 and improvement in AMA in one.9 Clinical features such as pruritus and fatigue improved significantly in only one trial.9 None of these trials reported an overall improvement in histological disease stage (defined using established criteria).41 In the trials in which specific histological criteria were examined, however, improvements in certain parameters such as hepatocellular ballooning, bile duct paucity, ductular proliferation, inflammatory cell infiltration, necrosis, and cholestasis were reported.9 23 40 Three of these trials used 'treatment failure', a composite end point including parameters such as biochemical deterioration, development of complications, withdrawal from the study, liver transplantation, and death.9 10 Completely reliable data on the longterm benefits of UDCA would ideally come from a large (eg, 1000 patients) longterm (eg, 10 years) double blind placebo controlled trial, but logistic difficulties prevent such a study. There is, however, some longer term survival data from open treatment studies. Two groups have reported sustained improvement in liver function tests after 6.5 years and improved survival compared to historical controls. 46 47 Recently Poupon et al48 published the four year follow up data on their original cohort of 146 patients. using the endpoint of 'death or liver transplantation', patients treated on UDCA for four years fared significantly better than those who had initially received two years of placebo followed by two years of UDCA. There are difficulties in using liver transplantation as an endpoint as these decisions are not based on fixed or fully objective criteria.
BETTER SURROGATE END POINTS
In a recent study we determined hepatic excretory function by measuring the plasma disappearance of injected 99mTcHIDA, before and during three months' treatment. There was significant improvement in the UDCA group compared with the placebo group. 49 Other groups have assessed the effects of UDCA using dynamic liver function tests (bromosulpthalein clearance test, aminopyrine breath tests, galactose excretion test) with conflicting results.5052
Floreani et a153 detected no change in serum markers of fibrosis (serum hyaluronate, type III procollagen amino propeptide) in PBC patients after two years of UDCA.
Future developments
The possibility that the efficacy of UDCA may be enhanced using combination therapy directed against immunological damage and fibrosis has stimulated some 
